COMMUNIQUÉS West-GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 13:00

RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired [...]

Augmedix to Participate in Upcoming Investor Conferences in May and June 2024

03/05/2024 - 13:00

SAN FRANCISCO, May 03, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced that its management team will participate in the following [...]

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

03/05/2024 - 13:00

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company [...]

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

03/05/2024 - 13:00

— Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO — — Company plans to present interim, first-in-human clinical data [...]

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

03/05/2024 - 13:00

– Trial did not meet primary endpoint – IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a [...]

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

03/05/2024 - 13:00

FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer [...]

Galera Adopts Limited Duration Stockholder Rights Agreement

03/05/2024 - 13:00

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to [...]

Aveanna to Participate at the Barclays Leveraged Finance Conference

03/05/2024 - 12:30

ATLANTA, May 03, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Barclays Leveraged Finance Conference in Austin, TX on May [...]

Immuron Director Resignation

03/05/2024 - 12:00

MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from [...]

PCI Biotech Holding ASA - Notice of Annual General Meeting 2024

03/05/2024 - 10:00

Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notice and proposed [...]

AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B

03/05/2024 - 09:00

MILAN, Italy, May 03, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for [...]

Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market

03/05/2024 - 09:00

Press release, Helsinki, 3 May 2024, 10 AM (EEST) Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that Nexstim, Inc. has [...]

Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration

03/05/2024 - 07:57

For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35 [...]

Trading statement Q1 2024

03/05/2024 - 07:56

Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4% with growth in both [...]

Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024

03/05/2024 - 07:15

Allschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections [...]

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock

03/05/2024 - 04:32

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of [...]

Avis de convocation à l’assemblée générale 2024 des actionnaires ONWARD® et propositions de résolutions

03/05/2024 - 03:31

EINDHOVEN, Pays-Bas, 03 mai 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale à l’origine de thérapies innovantes ciblées sur la restauration du mouvement, de la fonction et [...]

LUKE Named to 10-Year $43B Defense Health Agency IDIQ for the Medical Q-Coded Support and Services-Next Generation Program

03/05/2024 - 01:38

ROCKLEDGE, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- LUKE, a trusted leader in healthcare staffing for the U.S. Government, is proud to announce it has received a 10-year indefinite-delivery/indefinite-quantity (IDIQ) [...]

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

02/05/2024 - 23:13

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a [...]